| Year |
Citation |
Score |
| 2024 |
Lampejo AO, Lightsey SE, Gomes MC, Nguyen CM, Siemann DW, Sharma B, Murfee WL. A Novel Ex Vivo Tumor Spheroid-Tissue Model for Investigating Microvascular Remodeling and Lymphatic Blood Vessel Plasticity. Annals of Biomedical Engineering. PMID 38796670 DOI: 10.1007/s10439-024-03535-8 |
0.385 |
|
| 2023 |
Xin Y, Li K, Huang M, Liang C, Siemann D, Wu L, Tan Y, Tang X. Biophysics in tumor growth and progression: from single mechano-sensitive molecules to mechanomedicine. Oncogene. PMID 37864030 DOI: 10.1038/s41388-023-02844-x |
0.399 |
|
| 2022 |
Liang C, Huang M, Li T, Li L, Sussman H, Dai Y, Siemann DW, Xie M, Tang X. Towards an integrative understanding of cancer mechanobiology: calcium, YAP, and microRNA under biophysical forces. Soft Matter. PMID 35089300 DOI: 10.1039/d1sm01618k |
0.33 |
|
| 2020 |
Suarez-Martinez A, Sole-Gras M, Dykes SS, Wakefield ZR, Bauer K, Majbour D, Bundy A, Pampo C, Burow ME, Siemann DW, Huang Y, Murfee WL. Bioprinting on Live Tissue for Investigating Cancer Cell Dynamics. Tissue Engineering. Part A. PMID 33059528 DOI: 10.1089/ten.TEA.2020.0190 |
0.305 |
|
| 2020 |
Tanaka M, Siemann DW. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. Cancers. 12. PMID 32660000 DOI: 10.3390/Cancers12071850 |
0.466 |
|
| 2020 |
Suarez-Martinez AD, Sole-Gras M, Dykes SS, Wakefield ZR, Bauer K, Lampejo A, Siemann DW, Huang Y, Murfee WL. Abstract A23: A novel tumor microenvironment model that combines bioprinting and tissue culture to investigate cancer cell and microvascular interactions Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-A23 |
0.404 |
|
| 2020 |
Dai Y, Siemann D. Abstract 660: Combination of mTOR kinase inhibitors with Src inhibitors in PTEN-mt prostate cancer cells Cancer Research. 80: 660-660. DOI: 10.1158/1538-7445.Am2020-660 |
0.393 |
|
| 2020 |
Tanaka M, Siemann DW. Abstract 6114: Host and neoplastic cells utilize Axl for breast cancer bone metastasis Cancer Research. 80: 6114-6114. DOI: 10.1158/1538-7445.Am2020-6114 |
0.399 |
|
| 2020 |
Wakefield Z, Bundy A, Lepler S, Pampo C, Rice L, Siemann D. Abstract 2965: Aerobic exercise delays intraductal breast cancer growth and suppresses doxorubicin-induced skeletal and cardiac muscle toxicities Cancer Research. 80: 2965-2965. DOI: 10.1158/1538-7445.Am2020-2965 |
0.366 |
|
| 2020 |
Suarez-Martinez AD, Sole-Gras M, Dykes SS, Wakefield ZR, Bauer K, Lampejo A, Siemann DW, Huang Y, Murfee WL. A Novel Tumor Microenvironment Model that Combines Bioprinting and Tissue Culture to Investigate Cancer Cell and Microvascular Interactions The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05600 |
0.439 |
|
| 2019 |
Dykes SS, Fasanya HO, Siemann DW. Cathepsin L secretion by host and neoplastic cells potentiates invasion. Oncotarget. 10: 5560-5568. PMID 31565189 DOI: 10.18632/Oncotarget.27182 |
0.418 |
|
| 2019 |
Dai Y, Siemann D. c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells. Oncotargets and Therapy. 12: 3519-3529. PMID 31190858 DOI: 10.2147/Ott.S201320 |
0.405 |
|
| 2019 |
Tanaka M, Siemann DW. Axl signaling is an important mediator of tumor angiogenesis. Oncotarget. 10: 2887-2898. PMID 31080559 DOI: 10.18632/Oncotarget.26882 |
0.528 |
|
| 2019 |
Hughes VS, Siemann DW. Failures in preclinical and clinical trials of c-Met inhibitors: evaluation of pathway activity as a promising selection criterion. Oncotarget. 10: 184-197. PMID 30719213 DOI: 10.18632/Oncotarget.26546 |
0.394 |
|
| 2019 |
Siemann DW, Mendenhall WM. Role of Carbogen in the Treatment of Head and Neck Cancer. Cancer Control : Journal of the Moffitt Cancer Center. 6: 606-607. PMID 10756393 DOI: 10.1177/107327489900600613 |
0.439 |
|
| 2019 |
Dai Y, Siemann DW. Abstract 3914: mTOR pathway components dictate cell response to Src inhibitors in prostate cancer cells Cancer Research. 79: 3914-3914. DOI: 10.1158/1538-7445.Am2019-3914 |
0.393 |
|
| 2019 |
Dykes SS, Fasanya HO, Siemann DW. Abstract 3759: Host and neoplastic cell secretions of proteolytic enzymes potentiate metastasis Cancer Research. 79: 3759-3759. DOI: 10.1158/1538-7445.Am2019-3759 |
0.467 |
|
| 2019 |
Tanaka M, Siemann DW. Abstract 2849: Axl: A promising therapeutic target that leads to multimodal inhibition of the metastatic pathway Cancer Research. 79: 2849-2849. DOI: 10.1158/1538-7445.Am2019-2849 |
0.537 |
|
| 2018 |
Dykes SS, Hughes VS, Wiggins JM, Fasanya HO, Tanaka M, Siemann D. Stromal cells in breast cancer as a potential therapeutic target. Oncotarget. 9: 23761-23779. PMID 29805773 DOI: 10.18632/Oncotarget.25245 |
0.508 |
|
| 2018 |
Hughes VS, Wiggins JM, Siemann DW. Tumor oxygenation and cancer therapy-then and now. The British Journal of Radiology. 20170955. PMID 29513032 DOI: 10.1259/Bjr.20170955 |
0.5 |
|
| 2018 |
Dai Y, Siemann DW. Abstract B013: Combined molecular targeting Src and mTOR pathways to impair prostate cancer cell survival Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B013 |
0.406 |
|
| 2018 |
Dai Y, Siemann D. Abstract 2441: Effects of hypoxia on Src family members' activity in prostate cancer cells Cancer Research. 78: 2441-2441. DOI: 10.1158/1538-7445.Am2018-2441 |
0.409 |
|
| 2018 |
Dykes SS, Siemann DW. Abstract 186: Small-molecule inhibition of cathepsins L and K as potential therapeutics for macrophage-driven breast cancer Cancer Research. 78: 186-186. DOI: 10.1158/1538-7445.Am2018-186 |
0.356 |
|
| 2018 |
Hughes VS, Siemann DW. Abstract B157: Effect of HGF concentration on c-Met phosphorylation and inhibition in paracrine-activated tumor cells Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B157 |
0.466 |
|
| 2018 |
Dopico PJ, Fasanya H, Siemann DW, Fan HZ. 2090 TL1 team approach to osteosarcoma cell detection Journal of Clinical and Translational Science. 2: 33-33. DOI: 10.1017/cts.2018.140 |
0.318 |
|
| 2017 |
Wiggins JM, Opoku-Acheampong AB, Baumfalk DR, Siemann DW, Behnke BJ. Exercise and the Tumor Microenvironment: Potential Therapeutic Implications. Exercise and Sport Sciences Reviews. PMID 29166299 DOI: 10.1249/Jes.0000000000000137 |
0.455 |
|
| 2017 |
Siemann DW, Chaplin DJ, Horsman MR. Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation. 1-16. PMID 28872367 DOI: 10.1080/07357907.2017.1364745 |
0.456 |
|
| 2017 |
Wiggins JM, Lepler S, Pampo C, Rice L, Lee JA, Siemann D. Abstract 5913: The impact of daily exercise on tumor perfusion Cancer Research. 77: 5913-5913. DOI: 10.1158/1538-7445.Am2017-5913 |
0.429 |
|
| 2017 |
Fasanya H, Siemann D. Abstract 4899: The small molecule cathepsin L and K inhibitor KGP-94 impairs the metastatic phenotype of osteosarcoma cells Cancer Research. 77: 4899-4899. DOI: 10.1158/1538-7445.Am2017-4899 |
0.473 |
|
| 2017 |
Dai Y, Siemann DW. Abstract 4518: Impact of hypoxia on SFK activities in prostate cancer cells Cancer Research. 77: 4518-4518. DOI: 10.1158/1538-7445.Am2017-4518 |
0.317 |
|
| 2017 |
Hughes VS, Siemann DW. Abstract 3063: Predicting efficacy of c-Met targeting therapy in autocrine and paracrine tumor cell lines Cancer Research. 77: 3063-3063. DOI: 10.1158/1538-7445.Am2017-3063 |
0.423 |
|
| 2017 |
Dykes SS, Siemann DW. Abstract 2952: The novel cathepsin L/K inhibitors KGP94 and KGP207 prevent M0 to M2 macrophage differentiation and macrophage-mediated pro-tumor functions Cancer Research. 77: 2952-2952. DOI: 10.1158/1538-7445.Am2017-2952 |
0.303 |
|
| 2016 |
Shenoy AK, Jin Y, Luo H, Tang M, Pampo C, Shao R, Siemann DW, Wu L, Heldermon CD, Law BK, Chang LJ, Lu J. Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. The Journal of Clinical Investigation. PMID 27721239 DOI: 10.1172/Jci86623 |
0.503 |
|
| 2016 |
Sudhan DR, Rabaglino MB, Wood CE, Siemann DW. Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94. Clinical & Experimental Metastasis. PMID 27055649 DOI: 10.1007/S10585-016-9790-1 |
0.503 |
|
| 2016 |
Bosse RC, Wasserstrom B, Meacham A, Wise E, Drusbosky L, Walter GA, Chaplin DA, Siemann DW, Purich DL, Cogle CR. Chemosensitizing AML cells by Targeting Bone Marrow Endothelial Cells. Experimental Hematology. PMID 26898708 DOI: 10.1016/J.Exphem.2016.02.003 |
0.408 |
|
| 2016 |
Sudhan DR, Pampo C, Rice L, Siemann DW. Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model. International Journal of Cancer. 138: 2665-77. PMID 26757413 DOI: 10.1002/Ijc.29992 |
0.427 |
|
| 2016 |
Wiggins JM, Lee J, Rice L, Lepler S, Pampo C, Siemann D. Abstract 732: The impact of aerobic exercise on the tumor microenvironment Cancer Research. 76: 732-732. DOI: 10.1158/1538-7445.Am2016-732 |
0.423 |
|
| 2016 |
Hughes VS, Siemann DW. Abstract 4102: Effect of HGF concentrations on c-Met inhibition investigation Cancer Research. 76: 4102-4102. DOI: 10.1158/1538-7445.Am2016-4102 |
0.458 |
|
| 2016 |
Dai Y, Siemann D. Abstract 2792: Impact of hypoxia on tyrosine kinase activation in cancer cells Cancer Research. 76: 2792-2792. DOI: 10.1158/1538-7445.Am2016-2792 |
0.453 |
|
| 2015 |
Parker EN, Song J, Kishore Kumar GD, Odutola SO, Chavarria GE, Charlton-Sevcik AK, Strecker TE, Barnes AL, Sudhan DR, Wittenborn TR, Siemann DW, Horsman MR, Chaplin DJ, Trawick ML, Pinney KG. Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. Bioorganic & Medicinal Chemistry. PMID 26462052 DOI: 10.1016/J.Bmc.2015.09.036 |
0.4 |
|
| 2015 |
Sudhan DR, Siemann DW. Cathepsin L targeting in cancer treatment. Pharmacology & Therapeutics. 155: 105-16. PMID 26299995 DOI: 10.1016/J.Pharmthera.2015.08.007 |
0.374 |
|
| 2015 |
Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacology & Therapeutics. 153: 107-24. PMID 26073310 DOI: 10.1016/J.Pharmthera.2015.06.006 |
0.538 |
|
| 2015 |
Pham K, Luo D, Siemann DW, Law BK, Reynolds BA, Hothi P, Foltz G, Harrison JK. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner. Cancer Letters. 360: 60-7. PMID 25676691 DOI: 10.1016/J.Canlet.2015.02.005 |
0.497 |
|
| 2015 |
Salz T, Deng C, Pampo C, Siemann D, Qiu Y, Brown K, Huang S. Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in Breast Cancer. Molecular Cancer Research : McR. 13: 461-9. PMID 25373480 DOI: 10.1158/1541-7786.Mcr-14-0389 |
0.323 |
|
| 2015 |
Lee JA, Wiggins J, Siemann DW. Abstract B24: Impact of aerobic exercise on tumor oxygenation and perfusion in breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-B24 |
0.451 |
|
| 2015 |
Horsman MR, Siemann DW. Abstract A04: Is the lack of clinical success with antiangiogenic therapy due to vascular normalization not being a universal phenomenon? Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-A04 |
0.479 |
|
| 2015 |
Rice LP, Pampo C, Lepler S, Siemann DW. Abstract 777: Effects of Src inhibitors and soy isoflavones on human prostate cancer cells Cancer Research. 75: 777-777. DOI: 10.1158/1538-7445.Am2015-777 |
0.473 |
|
| 2015 |
Lee JA, Wiggins JM, Rice LP, Siemann DW. Abstract 5211: In vivo fluorescence and spectral microscopy of the effects of aerobic exercise on tumor oxygenation and perfusion in breast cancer Cancer Research. 75: 5211-5211. DOI: 10.1158/1538-7445.Am2015-5211 |
0.456 |
|
| 2015 |
Sudhan D, Rabaglino B, Wood C, Siemann D. Abstract 4185: Role of Cathepsin L in breast cancer angiogenesis Cancer Research. 75: 4185-4185. DOI: 10.1158/1538-7445.Am2015-4185 |
0.518 |
|
| 2015 |
Wiggins JM, Lee JA, Rice L, Siemann D. Abstract 3198: The impact of aerobic exercise on oxygenation and vascularity in breast cancer models Cancer Research. 75: 3198-3198. DOI: 10.1158/1538-7445.Am2015-3198 |
0.419 |
|
| 2015 |
Dai Y, Zhao L, Siemann DW. Abstract B59: Dual mTOR kinase inhibitor reverses rapamycin resistance in prostate cancer cells Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B59 |
0.41 |
|
| 2014 |
Biel NM, Siemann DW. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Letters. PMID 25312939 DOI: 10.1016/J.Canlet.2014.09.035 |
0.447 |
|
| 2014 |
Biel NM, Lee JA, Sorg BS, Siemann DW. Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesis. Vascular Cell. 6: 17. PMID 25101168 DOI: 10.1186/2045-824X-6-17 |
0.498 |
|
| 2014 |
Lee JA, Biel NM, Kozikowski RT, Siemann DW, Sorg BS. In vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors. Biomedical Optics Express. 5: 1965-79. PMID 24940553 DOI: 10.1364/Boe.5.001965 |
0.488 |
|
| 2014 |
McCullough DJ, Stabley JN, Siemann DW, Behnke BJ. Modulation of blood flow, hypoxia, and vascular function in orthotopic prostate tumors during exercise. Journal of the National Cancer Institute. 106: dju036. PMID 24627275 DOI: 10.1093/Jnci/Dju036 |
0.439 |
|
| 2014 |
Magdoom KN, Pishko GL, Rice L, Pampo C, Siemann DW, Sarntinoranont M. MRI-based computational model of heterogeneous tracer transport following local infusion into a mouse hind limb tumor. Plos One. 9: e89594. PMID 24619021 DOI: 10.1371/Journal.Pone.0089594 |
0.397 |
|
| 2014 |
Scharf VF, Farese JP, Siemann DW, Abbott JR, Kiupel M, Salute ME, Milner RJ. Effects of aurothiomalate treatment on canine osteosarcoma in a murine xenograft model. Anti-Cancer Drugs. 25: 332-9. PMID 24304691 DOI: 10.1097/Cad.0000000000000061 |
0.502 |
|
| 2014 |
Dai Y, Siemann D, Shi W. Abstract 5507: Activation of a subset of growth factor-associated genes in cetuximab-sensitive colorectal cancer GEO cells with KRAS mutation Cancer Research. 74: 5507-5507. DOI: 10.1158/1538-7445.Am2014-5507 |
0.616 |
|
| 2014 |
Rice LP, Pampo C, Lepler S, Siemann DW. Abstract 4037: Combining tyrosine kinase inhibitors and isoflavones to target metastatic activity in prostate cancer cells Cancer Research. 74: 4037-4037. DOI: 10.1158/1538-7445.Am2014-4037 |
0.42 |
|
| 2014 |
Sudhan DR, Siemann DW. Abstract 4030: In-vivo evaluation of the anti-metastatic efficacy of small molecule Cathepsin L inhibitor KGP94 in a prostate cancer model Cancer Research. 74: 4030-4030. DOI: 10.1158/1538-7445.Am2014-4030 |
0.449 |
|
| 2014 |
Wittenborn TR, Stratford M, Trawick ML, Pinney KG, Chaplin DJ, Siemann DW, Horsman MR. Abstract 1816: Assessment of anti-tumor activity of the cathepsin L inhibitor, KGP94 Cancer Research. 74: 1816-1816. DOI: 10.1158/1538-7445.Am2014-1816 |
0.452 |
|
| 2014 |
Pham K, Luo D, Siemann D, Law B, Reynolds B, Hothi P, Foltz G, Harrison J. AI-24 * VEGFR INHIBITORS ENHANCE PROGRESSION OF GLIOBLASTOMA BY UPREGULATING CXCR4 IN A TGF R SIGNALING-DEPENDENT MANNER Neuro-Oncology. 16: v6-v6. DOI: 10.1093/Neuonc/Nou238.24 |
0.491 |
|
| 2013 |
McCullough DJ, Nguyen LM, Siemann DW, Behnke BJ. Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. Journal of Applied Physiology (Bethesda, Md. : 1985). 115: 1846-54. PMID 24177690 DOI: 10.1152/Japplphysiol.00949.2013 |
0.406 |
|
| 2013 |
Sudhan DR, Siemann DW. Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells. Clinical & Experimental Metastasis. 30: 891-902. PMID 23748470 DOI: 10.1007/S10585-013-9590-9 |
0.515 |
|
| 2013 |
Scharf VF, Farese JP, Coomer AR, Milner RJ, Taylor DP, Salute ME, Chang MN, Neal D, Siemann DW. Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. American Journal of Veterinary Research. 74: 771-8. PMID 23627391 DOI: 10.2460/Ajvr.74.5.771 |
0.394 |
|
| 2013 |
Jaiswal AS, Panda H, Pampo CA, Siemann DW, Gairola CG, Hromas R, Narayan S. Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. Neoplasia (New York, N.Y.). 15: 454-60. PMID 23555190 DOI: 10.1593/Neo.13176 |
0.329 |
|
| 2013 |
Jia D, Hasso SM, Chan J, Filingeri D, D'Amore PA, Rice L, Pampo C, Siemann DW, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood. 121: 707-15. PMID 23212515 DOI: 10.1182/Blood-2012-05-433045 |
0.416 |
|
| 2013 |
Sefah K, Bae KM, Phillips JA, Siemann DW, Su Z, McClellan S, Vieweg J, Tan W. Cell-based selection provides novel molecular probes for cancer stem cells. International Journal of Cancer. Journal International Du Cancer. 132: 2578-88. PMID 23150432 DOI: 10.1002/Ijc.27936 |
0.486 |
|
| 2013 |
Molnar N, Siemann DW. Combined Ang-2 and VEGF Targeting Therapies in Renal Cell Carcinoma Journal of Cancer Therapy. 4: 1-6. DOI: 10.4236/Jct.2013.49A2001 |
0.461 |
|
| 2013 |
Dai Y, Bae K, Vieweg J, Siemann DW. Abstract A5: Functional role of SOX2 in hypoxia-mediated metastasis-associated functions in prostate cancer Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-A5 |
0.375 |
|
| 2013 |
Sudhan DR, Siemann DW. Abstract A33: Small molecule cathepsin L inhibitor KGP94 suppresses hypoxia and acidosis potentiated metastatic capacity of prostate and breast cancer cells Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-A33 |
0.433 |
|
| 2013 |
Dai Y, Bae K, Siemann DW. Abstract 927: Combined targeting c-Src and c-Met pathways to impair prostate cancer cell growth and invasion. Cancer Research. 73: 927-927. DOI: 10.1158/1538-7445.Am2013-927 |
0.331 |
|
| 2013 |
Molnar N, Siemann DW. Abstract 5094: Angiopoietin-2 antagonist enhances the anti-angiogenic effect of sunitinib in a preclinical renal cell carcinoma model. Cancer Research. 73: 5094-5094. DOI: 10.1158/1538-7445.Am2013-5094 |
0.505 |
|
| 2013 |
Sudhan DR, Siemann DW. Abstract 5093: Tumor angiogenesis: The role of Cathepsin L and its therapeutic intervention by the small molecule inhibitor KGP94. Cancer Research. 73: 5093-5093. DOI: 10.1158/1538-7445.Am2013-5093 |
0.544 |
|
| 2013 |
Rice LP, Pampo C, Lepler S, Siemann DW. Abstract 3946: Saracatinib inhibits human prostate cancer cell bone metastases in a xenograft model. Cancer Research. 73: 3946-3946. DOI: 10.1158/1538-7445.Am2013-3946 |
0.456 |
|
| 2012 |
Salmon HW, Guha A, Rojiani AM, Siemann DW. Vascular development in mouse lung metastases. American Journal of Cancer Research. 2: 581-8. PMID 22957309 |
0.397 |
|
| 2012 |
Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. Bmc Cancer. 12: 198. PMID 22639908 DOI: 10.1186/1471-2407-12-198 |
0.363 |
|
| 2012 |
Siemann DW, Dong M, Pampo C, Shi W. Src-signaling interference impairs the dissemination of blood-borne tumor cells. Cell and Tissue Research. 349: 541-50. PMID 22526632 DOI: 10.1007/S00441-012-1415-7 |
0.77 |
|
| 2012 |
Molnar N, Siemann DW. Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. Microvascular Research. 83: 290-7. PMID 22387475 DOI: 10.1016/J.Mvr.2012.02.008 |
0.473 |
|
| 2012 |
Dai Y, Bae K, Pampo C, Siemann DW. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clinical & Experimental Metastasis. 29: 253-61. PMID 22286523 DOI: 10.1007/S10585-011-9447-Z |
0.487 |
|
| 2012 |
Rice L, Lepler S, Pampo C, Siemann DW. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells. Clinical & Experimental Metastasis. 29: 133-42. PMID 22130962 DOI: 10.1007/S10585-011-9436-2 |
0.418 |
|
| 2012 |
Dai Y, Bae K, Siemann DW. Another road leads to HIF-1 activation: implications for prostate cancer progression. Asian Journal of Andrology. 14: 241-2. PMID 22101943 DOI: 10.1038/Aja.2011.163 |
0.403 |
|
| 2012 |
Cheng B, Ling C, Dai Y, Lu Y, Glushakova LG, Gee SW, McGoogan KE, Aslanidi GV, Park M, Stacpoole PW, Siemann D, Liu C, Srivastava A, Ling C. Development of optimized AAV3 serotype vectors: mechanism of high-efficiency transduction of human liver cancer cells. Gene Therapy. 19: 375-84. PMID 21776025 DOI: 10.1038/Gt.2011.105 |
0.36 |
|
| 2012 |
Dai Y, Siemann DW. Abstract 3761: Efficacy of the ATP-competitive mTOR inhibitor AZD8055 in PTEN-wild type cancer cells Cancer Research. 72: 3761-3761. DOI: 10.1158/1538-7445.Am2012-3761 |
0.434 |
|
| 2012 |
Lee J, Kozikowski R, Molnar N, Siemann DW, Sorg BS. In vivo spectral and fluorescence imaging microscopy of tumor microvessel blood supply and oxygenation changes following vascular targeting agent treatment Progress in Biomedical Optics and Imaging - Proceedings of Spie. 8222. DOI: 10.1117/12.905113 |
0.462 |
|
| 2011 |
Tang M, Chen B, Lin T, Li Z, Pardo C, Pampo C, Chen J, Lien CL, Wu L, Ai L, Wang H, Yao K, Oh SP, Seto E, Smith LE, ... Siemann DW, et al. Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. Proceedings of the National Academy of Sciences of the United States of America. 108: 15231-6. PMID 21896759 DOI: 10.1073/Pnas.1104662108 |
0.359 |
|
| 2011 |
Bertelsen LB, Shen YY, Nielsen T, Stødkilde-Jørgensen H, Lloyd GK, Siemann DW, Horsman MR. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology. 87: 1126-34. PMID 21815749 DOI: 10.3109/09553002.2011.605418 |
0.33 |
|
| 2011 |
Dai Y, Bae K, Siemann DW. Impact of hypoxia on the metastatic potential of human prostate cancer cells. International Journal of Radiation Oncology, Biology, Physics. 81: 521-8. PMID 21640519 DOI: 10.1016/J.Ijrobp.2011.04.027 |
0.347 |
|
| 2011 |
Rice L, Pampo C, Lepler S, Rojiani AM, Siemann DW. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvascular Research. 81: 44-51. PMID 20974154 DOI: 10.1016/J.Mvr.2010.10.003 |
0.488 |
|
| 2011 |
Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treatment Reviews. 37: 63-74. PMID 20570444 DOI: 10.1016/J.Ctrv.2010.05.001 |
0.518 |
|
| 2011 |
Romero-Ramirez L, Cao H, Regalado MP, Kambham N, Siemann D, Kim JJ, Le QT, Koong AC. X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. Translational Oncology. 2: 31-8. PMID 19252749 DOI: 10.1593/Tlo.08211 |
0.475 |
|
| 2011 |
Bae K, Dai Y, Vieweg J, Siemann D. Abstract 485: Hypoxia increases the expression of stem-cell markers and promotes cell invasion in prostate cancer cells Cancer Research. 71: 485-485. DOI: 10.1158/1538-7445.Am2011-485 |
0.385 |
|
| 2011 |
Dai Y, Siemann D. Abstract 4495: Treatment effects of the novel mTOR kinase inhibitor AZD8055 in prostate cancer cell models Cancer Research. 71: 4495-4495. DOI: 10.1158/1538-7445.Am2011-4495 |
0.41 |
|
| 2011 |
Molnar N, Siemann DW. Abstract 4269: Human monoclonal anti-angiopoietin-2 antibody, MEDI3617, inhibits angiogenesis in preclinical studies Cancer Research. 71: 4269-4269. DOI: 10.1158/1538-7445.Am2011-4269 |
0.467 |
|
| 2011 |
Sudhan DR, Siemann DW. Abstract 1422: Abrogation of prostate cancer cell metastatic phenotype by cathepsin-L inhibition Cancer Research. 71: 1422-1422. DOI: 10.1158/1538-7445.Am2011-1422 |
0.367 |
|
| 2011 |
Molnar N, Siemann DW. Abstract B5: Tumor-cell-induced angiopoietin-2 secretion from endothelial cells results in destabilization of the endothelial/smooth muscle cell interaction of blood vessels. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B5 |
0.454 |
|
| 2011 |
Saffran V, Siemann D. Abstract B151: Src inhibitor dasatinib reduces the metastatic phenotype of breast cancer cells. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B151 |
0.522 |
|
| 2011 |
Sudhan DR, Siemann DW. Abstract B150: Cathepsin L targeting abrogates tumor microenvironment enhanced metastatic potential in prostate cancer cells. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B150 |
0.481 |
|
| 2010 |
Dong M, Rice L, Lepler S, Pampo C, Siemann DW. Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model. Anticancer Research. 30: 4405-13. PMID 21115886 |
0.613 |
|
| 2010 |
Baguley BC, Siemann DW. Temporal aspects of the action of ASA404 (vadimezan; DMXAA). Expert Opinion On Investigational Drugs. 19: 1413-25. PMID 20964495 DOI: 10.1517/13543784.2010.529128 |
0.481 |
|
| 2010 |
Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Molecular Cancer Therapeutics. 9: 1554-61. PMID 20515943 DOI: 10.1158/1535-7163.Mct-10-0359 |
0.404 |
|
| 2010 |
Madlambayan GJ, Meacham AM, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood. 116: 1539-47. PMID 20472832 DOI: 10.1182/Blood-2009-06-230474 |
0.411 |
|
| 2010 |
Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. The Journal of Urology. 183: 2045-53. PMID 20303530 DOI: 10.1016/J.Juro.2009.12.092 |
0.429 |
|
| 2010 |
Wankhede M, Dedeugd C, Siemann DW, Sorg BS. In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. Oncology Reports. 23: 685-92. PMID 20127007 DOI: 10.3892/Or_00000685 |
0.482 |
|
| 2010 |
Rojiani MV, Siemann DW, Rojiani AM. Cell proliferation index determination by immunohistochemical detection of hCDC47 protein. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 18: 278-82. PMID 20048674 DOI: 10.1097/Pai.0B013E3181C6C949 |
0.357 |
|
| 2010 |
Bae K, Parker N, Vieweg J, Siemann D. 470 E-cadherin plasticity in tumor-initiating stem-like cells regulates prostate cancer cell invasion European Journal of Cancer Supplements. 8: 151. DOI: 10.1016/S1359-6349(10)72177-7 |
0.301 |
|
| 2009 |
Madlambayan GJ, Butler JM, Hosaka K, Jorgensen M, Fu D, Guthrie SM, Shenoy AK, Brank A, Russell KJ, Otero J, Siemann DW, Scott EW, Cogle CR. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood. 114: 4310-9. PMID 19717647 DOI: 10.1182/Blood-2009-03-211342 |
0.318 |
|
| 2009 |
Siemann DW, Norris CM, Ryan A, Shi W. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Research. 29: 1987-92. PMID 19528456 |
0.631 |
|
| 2009 |
Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opinion On Investigational Drugs. 18: 189-97. PMID 19236265 DOI: 10.1517/13543780802691068 |
0.495 |
|
| 2009 |
Siemann DW, Brazelle WD, Jürgensmeier JM. The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts. International Journal of Radiation Oncology, Biology, Physics. 73: 897-903. PMID 19215823 DOI: 10.1016/J.Ijrobp.2008.10.031 |
0.41 |
|
| 2009 |
Coomer AR, Farese JP, Milner R, Taylor D, Salute ME, Rajon DA, Bova FJ, Siemann DW. Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapy. American Journal of Veterinary Research. 70: 127-33. PMID 19119958 DOI: 10.2460/Ajvr.70.1.127 |
0.36 |
|
| 2009 |
Siemann DW, Horsman MR. Vascular targeted therapies in oncology. Cell and Tissue Research. 335: 241-8. PMID 18752004 DOI: 10.1007/S00441-008-0646-0 |
0.506 |
|
| 2009 |
Madlambayan GJ, Meacham A, Hosaka K, Mir S, Jorgensen M, Scott EW, Siemann DW, Cogle CR. AML Regression by Vascular Disruption with OXi4503 and Anti-Angiogenesis with Bevacizumab. Blood. 114: 1031-1031. DOI: 10.1182/Blood.V114.22.1031.1031 |
0.338 |
|
| 2009 |
Dai Y, Siemann D. Abstract C190: BMS‐777607, a potent small molecule c‐MET inhibitor, inhibits prostate cancer progression in vitro Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C190 |
0.395 |
|
| 2009 |
Siemann DW, Dong M. Abstract B107: Targeting metastatic tumor cell functions by Src signaling interference using the small molecule Src inhibitor, saracatinib (AZD0530) Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B107 |
0.707 |
|
| 2008 |
Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Research. 28: 2027-31. PMID 18751370 |
0.568 |
|
| 2008 |
Kusmartsev S, Eruslanov E, Kübler H, Tseng T, Sakai Y, Su Z, Kaliberov S, Heiser A, Rosser C, Dahm P, Siemann D, Vieweg J. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. Journal of Immunology (Baltimore, Md. : 1950). 181: 346-53. PMID 18566400 DOI: 10.4049/Jimmunol.181.1.346 |
0.499 |
|
| 2008 |
Siemann D, Dong M. 575 POSTER Targeting metastatic tumor cell functions by inhibition of new blood vessel formation with the selective VEGF signal inhibitor, cediranib (RECENTIN™, AZD2171) or Src signaling interference using the small molecule Src inhibitor, AZD0530 European Journal of Cancer Supplements. 6: 180-181. DOI: 10.1016/S1359-6349(08)72509-6 |
0.315 |
|
| 2007 |
Siemann DW, Chaplin DJ. An update on the clinical development of drugs to disable tumor vasculature. Expert Opinion On Drug Discovery. 2: 1357-67. PMID 23484531 DOI: 10.1517/17460441.2.10.1357 |
0.482 |
|
| 2007 |
Salmon BA, Salmon HW, Siemann DW. Monitoring the treatment efficacy of the vascular disrupting agent CA4P. European Journal of Cancer (Oxford, England : 1990). 43: 1622-9. PMID 17451938 DOI: 10.1016/J.Ejca.2007.03.018 |
0.306 |
|
| 2007 |
Salmon BA, Siemann DW. Characterizing the tumor response to treatment with combretastatin A4 phosphate. International Journal of Radiation Oncology, Biology, Physics. 68: 211-7. PMID 17448875 DOI: 10.1016/J.Ijrobp.2006.12.051 |
0.365 |
|
| 2007 |
Cogle CR, Brank A, Siemann D, Scott EW. The Hematopoietic Stem Cell Is a Source of Endothelial Cells in Cancer Vasculogenesis and Depends on SDF-1. Blood. 110: 3722-3722. DOI: 10.1182/Blood.V110.11.3722.3722 |
0.504 |
|
| 2006 |
Norris CM, Shi W, Siemann DW. Impact of VEGF expression on the physiological characteristics of clonal cell lines. In Vivo (Athens, Greece). 20: 815-21. PMID 17203773 |
0.567 |
|
| 2006 |
Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Research. 66: 11520-39. PMID 17178843 DOI: 10.1158/0008-5472.CAN-06-2848 |
0.422 |
|
| 2006 |
Shi W, Siemann DW. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Research. 26: 3445-53. PMID 17094465 |
0.56 |
|
| 2006 |
Salmon HW, Mladinich C, Siemann DW. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. European Journal of Cancer (Oxford, England : 1990). 42: 3073-8. PMID 16956760 DOI: 10.1016/J.Ejca.2006.06.016 |
0.372 |
|
| 2006 |
Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4090-4. PMID 16818709 DOI: 10.1158/1078-0432.Ccr-06-0163 |
0.372 |
|
| 2006 |
Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Current Opinion in Investigational Drugs (London, England : 2000). 7: 522-8. PMID 16784022 |
0.352 |
|
| 2006 |
Brazelle WD, Shi W, Siemann DW. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. International Journal of Radiation Oncology, Biology, Physics. 65: 836-41. PMID 16751064 DOI: 10.1016/J.Ijrobp.2006.02.023 |
0.601 |
|
| 2006 |
Teschendorf C, Warrington KH, Shi W, Siemann DW, Muzyczka N. Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma. Anticancer Research. 26: 311-7. PMID 16475712 |
0.761 |
|
| 2006 |
Salmon HW, Mladinich C, Siemann DW. Evaluations of the renal cell carcinoma model Caki-1 using a silicon based microvascular casting technique. Technology in Cancer Research & Treatment. 5: 45-51. PMID 16417401 DOI: 10.1177/153303460600500106 |
0.43 |
|
| 2006 |
Otero J, Russell KJ, Fu D, Shi W, Jorgensen ML, Guthrie SM, Siemann D, Scott EW, Cogle CR. Tumor Vasculogenesis Can Be Derived from the Hematopoietic Stem Cell. Blood. 108: 1806-1806. DOI: 10.1182/Blood.V108.11.1806.1806 |
0.676 |
|
| 2006 |
Siemann D. 27 Molecular modulation of the tumor vasculature — Impact on tumor response to radiation therapy Radiotherapy and Oncology. 78: S10. DOI: 10.1016/S0167-8140(06)80521-9 |
0.337 |
|
| 2005 |
Shi W, Siemann DW. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Research. 25: 3899-904. PMID 16309177 |
0.615 |
|
| 2005 |
Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo (Athens, Greece). 19: 1045-50. PMID 16277020 |
0.572 |
|
| 2005 |
Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. International Journal of Radiation Oncology, Biology, Physics. 62: 846-53. PMID 15936569 DOI: 10.1016/J.Ijrobp.2005.02.048 |
0.538 |
|
| 2005 |
Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, Marmé D, Lorusso PM. Differentiation and definition of vascular-targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 416-20. PMID 15701823 |
0.331 |
|
| 2004 |
Salmon HW, Siemann DW. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 73: 359-66. PMID 15588883 DOI: 10.1016/J.Radonc.2004.07.018 |
0.408 |
|
| 2004 |
Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. International Journal of Radiation Oncology, Biology, Physics. 60: 1233-40. PMID 15519796 DOI: 10.1016/J.Ijrobp.2004.08.002 |
0.654 |
|
| 2004 |
Siemann DW. Therapeutic strategies that selectively target and disrupt established tumor vasculature. Hematology/Oncology Clinics of North America. 18: 1023-37, viii. PMID 15474333 DOI: 10.1016/J.Hoc.2004.06.012 |
0.427 |
|
| 2004 |
Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 100: 2491-9. PMID 15197790 DOI: 10.1002/Cncr.20299 |
0.518 |
|
| 2004 |
Siemann DW, Horsman MR. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Review of Anticancer Therapy. 4: 321-7. PMID 15056061 DOI: 10.1586/14737140.4.2.321 |
0.526 |
|
| 2004 |
Shi W, Siemann DW. Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach. Anticancer Research. 24: 213-8. PMID 15015599 |
0.549 |
|
| 2004 |
Siemann D, Shi W. Monoclonal Antibodies Against 4-1BB Enhance the Antitumor Effects of Radiation Journal of Immunotherapy. 27: S11. DOI: 10.1097/00002371-200411000-00044 |
0.449 |
|
| 2003 |
Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 66: 1-9. PMID 12559515 DOI: 10.1016/S0167-8140(02)00280-3 |
0.651 |
|
| 2003 |
Siemann DW, Shi W. Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy Seminars in Radiation Oncology. 13: 53-61. PMID 12520464 DOI: 10.1053/Srao.2003.50005 |
0.679 |
|
| 2002 |
Teschendorf C, Warrington KH, Siemann DW, Muzyczka N. Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Research. 22: 3325-30. PMID 12530082 |
0.696 |
|
| 2002 |
Siemann DW, Horsman MR. Enhancement of radiation therapy by vascular targeting agents. Current Opinion in Investigational Drugs (London, England : 2000). 3: 1660-5. PMID 12476970 |
0.409 |
|
| 2002 |
Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. International Journal of Radiation Oncology, Biology, Physics. 54: 1512-7. PMID 12459379 DOI: 10.1016/S0360-3016(02)03919-6 |
0.521 |
|
| 2002 |
Shi W, Siemann DW. Inhibition of renal cell carcinoma angiogenesis and growth by antisense oligonucleotides targeting vascular endothelial growth factor British Journal of Cancer. 87: 119-126. PMID 12085267 DOI: 10.1038/sj.bjc.6600416 |
0.545 |
|
| 2002 |
Shi W, Teschendorf C, Muzyczka N, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Therapy. 9: 513-21. PMID 12032662 DOI: 10.1038/Sj.Cgt.7700463 |
0.654 |
|
| 2002 |
Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation Oncology, Biology, Physics. 53: 164-71. PMID 12007956 DOI: 10.1016/S0360-3016(02)02742-6 |
0.531 |
|
| 2002 |
Rojiani AM, Li L, Rise L, Siemann DW. Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma. Acta Oncologica (Stockholm, Sweden). 41: 98-105. PMID 11990526 DOI: 10.1080/028418602317314136 |
0.486 |
|
| 2002 |
Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncologica (Stockholm, Sweden). 41: 91-7. PMID 11990525 |
0.395 |
|
| 2002 |
Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. International Journal of Cancer. Journal International Du Cancer. 99: 1-6. PMID 11948484 DOI: 10.1002/Ijc.10316 |
0.481 |
|
| 2002 |
Siemann DW. Vascular targeting agents International Journal of Radiation Oncology*Biology*Physics. 54: 1472. DOI: 10.1016/S0360-3016(02)04141-X |
0.317 |
|
| 2001 |
Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiation Research. 156: 503-9. PMID 11604063 DOI: 10.1667/0033-7587(2001)156[0503:Itrbcr]2.0.Co;2 |
0.404 |
|
| 2001 |
Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 60: 155-61. PMID 11439210 DOI: 10.1016/S0167-8140(01)00384-X |
0.442 |
|
| 2000 |
Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels: an adjuvant strategy for radiation therapy. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 57: 5-12. PMID 11033183 DOI: 10.1016/S0167-8140(00)00243-7 |
0.764 |
|
| 1999 |
Pero RW, Axelsson B, Siemann D, Chaplin D, Dougherty G. Molecular and Cellular Biochemistry. 193: 119-125. DOI: 10.1023/A:1006932714982 |
0.307 |
|
| 1998 |
Warrington KH, Teschendorf C, Cao L, Muzyczka N, Siemann DW. Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid. International Journal of Radiation Oncology, Biology, Physics. 42: 909-12. PMID 9845120 DOI: 10.1016/S0360-3016(98)00357-5 |
0.709 |
|
| 1998 |
Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 42: 899-903. PMID 9845118 DOI: 10.1016/S0360-3016(98)00320-4 |
0.508 |
|
| 1998 |
Siemann DW. The tumor microenvironment: a double-edged sword. International Journal of Radiation Oncology, Biology, Physics. 42: 697-9. PMID 9845079 DOI: 10.1016/S0360-3016(98)00336-8 |
0.442 |
|
| 1998 |
Siemann DW, Hinchman CA. Potentiation of cisplatin activity by the bioreductive agent tirapazamine. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 47: 215-20. PMID 9683372 DOI: 10.1016/S0167-8140(97)00224-7 |
0.463 |
|
| 1998 |
Keng PC, Siemann DW. Measurement of proliferation activities in human tumor models: a comparison of flow cytometric methods. Radiation Oncology Investigations. 6: 120-7. PMID 9652910 DOI: 10.1002/(Sici)1520-6823(1998)6:3<120::Aid-Roi2>3.0.Co;2-# |
0.423 |
|
| 1998 |
Siemann DW, Johansen IM, Horsman MR. Radiobiological hypoxia in the KHT sarcoma: predictions using the Eppendorf histograph. International Journal of Radiation Oncology, Biology, Physics. 40: 1171-6. PMID 9539574 DOI: 10.1016/S0360-3016(98)00004-2 |
0.372 |
|
| 1997 |
Richardson ME, Siemann DW. Tumor cell heterogeneity: Impact on mechanisms of therapeutic drug resistance International Journal of Radiation Oncology Biology Physics. 39: 789-795. PMID 9369124 DOI: 10.1016/S0360-3016(97)00469-0 |
0.35 |
|
| 1997 |
Kiani MF, Fenton BM, Sporn LA, Siemann DW. Effects of ionizing radiation on the adhesive interaction of human tumor and endothelial cells in vitro. Clinical & Experimental Metastasis. 15: 12-8. PMID 9009101 DOI: 10.1023/A:1018424021393 |
0.495 |
|
| 1996 |
Lee J, Siemann DW, Koch CJ, Lord EM. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts International Journal of Cancer. 67: 372-378. PMID 8707411 DOI: 10.1002/(Sici)1097-0215(19960729)67:3<372::Aid-Ijc11>3.0.Co;2-A |
0.508 |
|
| 1995 |
Naylor MA, Adams GE, Haigh A, Cole S, Jenner T, Robertson N, Siemann D, Stephens MA, Stratford IJ. Fused pyrazine mono-N-oxides as bioreductive drugs. III. Characterization of RB 90740 in vitro and in vivo. Anti-Cancer Drugs. 6: 259-69. PMID 7795274 DOI: 10.1097/00001813-199504000-00010 |
0.386 |
|
| 1995 |
Siemann DW. Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 34: 47-53. PMID 7792398 DOI: 10.1016/0167-8140(94)01498-R |
0.316 |
|
| 1995 |
Fenton BM, Siemann DW. Are direct measures of tumor oxygenation reflective of changes in tumor radiosensitivity following oxygen manipulation? Acta Oncologica (Stockholm, Sweden). 34: 307-11. PMID 7779414 DOI: 10.3109/02841869509093980 |
0.355 |
|
| 1995 |
Fenton BM, Kiani MF, Siemann DW. Should direct measurements of tumor oxygenation relate to the radiobiological hypoxic fraction of a tumor? International Journal of Radiation Oncology, Biology, Physics. 33: 365-373. PMID 7673024 DOI: 10.1016/0360-3016(95)00064-6 |
0.364 |
|
| 1994 |
Siemann DW. In vitro cytotoxicity and chemosensitizing activity of the dual function nitroimidazole RB 6145. International Journal of Radiation Oncology, Biology, Physics. 29: 301-6. PMID 8195023 DOI: 10.1016/0360-3016(94)90279-8 |
0.307 |
|
| 1994 |
Siemann DW, Horsman MR, Chaplin DJ. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing Radiotherapy and Oncology. 31: 117-122. PMID 8066190 DOI: 10.1016/0167-8140(94)90391-3 |
0.311 |
|
| 1994 |
Horsman MR, Khalil AA, Siemann DW, Grau C, Hill SA, Lynch EM, Chaplin DJ, Overgaard J. Relationship between radiobiological hypoxia in tumors and electrode measurements of tumor oxygenation. International Journal of Radiation Oncology, Biology, Physics. 29: 439-42. PMID 8005796 DOI: 10.1016/0360-3016(94)90434-0 |
0.31 |
|
| 1992 |
Siemann DW. Cytotoxicity of dual function nitrofurans in rodent and human tumor cells. International Journal of Radiation Oncology, Biology, Physics. 22: 697-700. PMID 1544840 DOI: 10.1016/0360-3016(92)90506-D |
0.353 |
|
| 1992 |
Chapuis JC, Keng PC, Siemann DW. Activity of etoposide (VP-16) and teniposide (VM-26) in exponential and plateau phase human tumor cell cultures. Anti-Cancer Drugs. 3: 245-52. PMID 1525405 DOI: 10.1097/00001813-199206000-00007 |
0.404 |
|
| 1992 |
Siemann DW, Sutherland RM. Potentiation of alkylating chemotherapy by dual function nitrofurans in multi-cell spheroids and solid tumors. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 24: 239-45. PMID 1410579 DOI: 10.1016/0167-8140(92)90230-R |
0.353 |
|
| 1990 |
Keng PC, Allalunis-Turner J, Siemann DW. Evaluation of cell subpopulations isolated from human tumor xenografts by centrifugal elutriation. International Journal of Radiation Oncology, Biology, Physics. 18: 1061-7. PMID 2347715 DOI: 10.1016/0360-3016(90)90441-L |
0.323 |
|
| 1989 |
Siemann DW, Alliet KL, Macler LM. Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 16: 1169-72. PMID 2715065 DOI: 10.1016/0360-3016(89)90276-9 |
0.338 |
|
| 1989 |
Siemann DW. The chemosensitizing and cytotoxic effects of RSU 1164 and RSU 1165 in a murine tumor model. International Journal of Radiation Oncology, Biology, Physics. 16: 1115-8. PMID 2703392 DOI: 10.1016/0360-3016(89)90929-2 |
0.332 |
|
| 1988 |
Siemann DW, Allalunis-Turner MJ. Potentiation of combination chemotherapy by nitroheterocyclics. International Journal of Radiation Oncology, Biology, Physics. 15: 129-34. PMID 3391809 DOI: 10.1016/0360-3016(88)90356-2 |
0.363 |
|
| 1988 |
Moulder JE, Dutreix J, Rockwell S, Siemann DW. Applicability of animal tumor data to cancer therapy in humans International Journal of Radiation Oncology, Biology, Physics. 14: 913-927. PMID 3283086 DOI: 10.1016/0360-3016(88)90014-4 |
0.326 |
|
| 1987 |
Siemann DW, Alliet KL. Potentiation of CCNU activity by misonidazole in metastases. Clinical & Experimental Metastasis. 5: 57-63. PMID 3829497 DOI: 10.1007/BF00116626 |
0.35 |
|
| 1985 |
Siemann DW, Mulcahy RT. Characterization of growth and radiation response of KHT tumor cells metastatic from lung to ovary and kidney. Clinical & Experimental Metastasis. 2: 73-81. PMID 6543692 DOI: 10.1007/BF00132308 |
0.305 |
|
| 1984 |
Siemann DW, Maddison K, Wolf K. Potentiation of melphalan activity in the KHT sarcoma by the radiosensitizer RSU 1069. International Journal of Radiation Oncology, Biology, Physics. 10: 1657-60. PMID 6548212 DOI: 10.1016/0360-3016(84)90522-4 |
0.312 |
|
| 1984 |
Siemann DW, Hill SA. Enhanced tumor responses through therapies combining CCNU, MISO and radiation. International Journal of Radiation Oncology, Biology, Physics. 10: 1623-6. PMID 6480451 DOI: 10.1016/0360-3016(84)90515-7 |
0.316 |
|
| 1984 |
Hill SA, Keng PC, Siemann DW. Survival in subpopulations of cells derived from solid KHT sarcomas by centrifugal elutriation following treatment with CCNU and MISO. International Journal of Radiation Oncology, Biology, Physics. 10: 1615-8. PMID 6480449 DOI: 10.1016/0360-3016(84)90513-3 |
0.34 |
|
| 1984 |
Siemann DW, Keng PC. In situ radiation response and oxygen enhancement ratio of KHT sarcoma cells in various phases of the cell cycle. The British Journal of Radiology. 57: 823-7. PMID 6478140 DOI: 10.1259/0007-1285-57-681-823 |
0.351 |
|
| 1981 |
Keng PC, Wheeler KT, Siemann DW, Lord EM. Direct synchronization of cells from solid tumors by centrifugal elutriation. Experimental Cell Research. 134: 15-22. PMID 7250214 DOI: 10.1016/0014-4827(81)90458-4 |
0.358 |
|
| 1981 |
Siemann DW, Kochanski K. Combinations of Radiation and Misonidazole in a Murine Lung Tumor Model Radiation Research. 86: 387. DOI: 10.2307/3575513 |
0.366 |
|
| 1980 |
Siemann DW, Sutherland RM. The Interaction between Adriamycin and Radiation in a Solid Murine Tumor Radiation Research. 83: 345. DOI: 10.2307/3575285 |
0.414 |
|
| 1979 |
Siemann DW, Hill RP, Bush RS. Smoking: the influence of carboxyhemoglobin (HbCO) on tumor oxygenation and response to radiation. International Journal of Radiation Oncology, Biology, Physics. 4: 657-62. PMID 711537 DOI: 10.1016/0360-3016(78)90189-X |
0.46 |
|
| 1979 |
Siemann DW, Hill RP, Bush RS, Chhabra P. The in vivo radiation response of an experimental tumor: the effect of exposing tumor-bearing mice to a reduced oxygen environment prior to but not during irradiation. International Journal of Radiation Oncology, Biology, Physics. 5: 61-8. PMID 422416 DOI: 10.1016/0360-3016(79)90039-7 |
0.326 |
|
| Show low-probability matches. |